Audit: QRS - Palmitoyl Tripeptide-5 for Skin Rejuvenation
Audit conducted on 26/06/2026 12:37 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 86 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS content (at-a-glance, benefits, risks, protocol, gates, monitoring) traces to ER passages. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Speculative” tier, “theoretical concern with broad TGF-β activation”, “not yet firmly proven” mirror ER caution. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy listed as precautionary contraindication, consistent with ER’s precautionary framing. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and interactions drawn from ER’s Key Interactions & Contraindications section; no cross-category relabeling. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Brand names “Syn-Coll”, “Matrixyl” appear in ER; no PMIDs/NCTs introduced. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions beyond those in ER. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, evidence-weighted tone matches ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Plain-language, balanced presentation. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, no directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Footer disclaimer; body presents information only. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending/advising verbs in own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms minimized; plain phrasing used. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Cards/cells are terse. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing fits optimization-oriented audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol/monitoring detail assumes engaged audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framed. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Modest-benefit, low-risk framing appropriate. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | “Rejuvenation”/”firmness” used; no “anti-aging” in own voice. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Formal register maintained. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring table headers (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings/labels present verbatim. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 42 data-qrs-var spans present, matching template set. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Hidden tier/time placeholders left at template defaults. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section used to populate the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Cadence/marker rows draw on ER labels faithfully. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Tier and section labels intact. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in rendered content. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to single-page layout. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment block at lines 2-14, first element. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | ”—” delimiters at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only “duration” quoted (contains colon); rest unquoted/trimmed. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: palmitoyl_tripeptide_5_skin_2026-0626-1158_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.5.18 (line 5). |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | qrs_creation_date: 2026-0626-1158 (line 6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” is single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier | 🟢 | “Opus 4.8” — nickname + version only. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: palmitoyl_tripeptide_5_skin_2026-0626-1158_Opus_QRS.html (line 9). |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Palmitoyl Tripeptide-5 for Skin Rejuvenation - Quick Reference Sheet”; no entities required. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Palmitoyl Tripeptide-5 for Skin Rejuvenation” (line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | “06/26/2026” (line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8” (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and standard subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER conclusion (mechanism, gentleness, weak/sponsor-led evidence, modest benefit). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Collagen signalling, mild irritation, company-funded weak evidence all in ER conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain terms (“firm skin”, “make more collagen”); no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect sizes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER’s “Populations who should avoid or use caution” bullet (line 225). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Active dermatitis/open skin, known allergy, pregnancy/breastfeeding (precautionary). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Three <li> entries (lines 542-544). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact. | 🟢 | Items terse; no trailing dash clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. | 🟢 | “(precautionary)” preserved for pregnancy/breastfeeding. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation present in source bullet. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER interaction bullets (lines 217-221). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Topical actives, peptides/growth factors, vitamin C; no overlap with contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Three <li> entries (lines 552-554). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact. | 🟢 | No trailing dash clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. | 🟢 | Example lists preserved: “(retinoids, glycolic/salicylic acid, benzoyl peroxide)”, “(Matrixyl, copper peptides)”. |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list. | 🟢 | No ranking notation present. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Application, concentration, timing drawn from ER Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Application (twice daily), concentration (~4%), best time of day. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects are present. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action cells populated from ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Firmness and fine lines (8–12 weeks) populated; only two distinct aspects exist in ER. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Firmness (headline benefit) precedes fine lines, matching ER benefit ordering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | Third set is display:none (line 503); unchanged template default. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both visible sets reflect ER’s ~8–12-week, two-month timelines. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Low and Speculative items match ER benefit subheadings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare benefit phrases, no effect sizes. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried over. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High and Medium spans set to display:none (lines 521, 524). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Low and Speculative items match ER risk subheadings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Concise fact-only phrasing. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried over. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High and Medium spans set to display:none (lines 566, 569). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker and cadence drawn from ER Monitoring Protocol. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | Serum 25-hydroxyvitamin D (the only biomarker in ER table) listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | “Reassess at 4, 8, and 12 weeks, then every 3–6 months if continuing” (line 608). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from ER qualitative markers list (lines 326-330). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five qualitative markers reproduced verbatim. |
Issues 26/06/2026 12:37
Pass rate 100.00%. No issues found.
Issues 26/06/2026 12:35
- 1.3 — At-a-glance overstates safety: The at-a-glance states “no whole-body effects”, strengthening the ER Conclusion’s hedged “no meaningful whole-body effects expected from topical use” (ER line 350) into an absolute claim.
Fixes 26/06/2026 12:35
- 1.3 — At-a-glance overstates safety: Changed “no whole-body effects” to “no meaningful whole-body effects expected” to match the ER Conclusion’s hedged wording.
Issues 26/06/2026 12:30
- 10.2 — Action sourced outside Protocol: action_3 (“Onboarding — Patch test, then ramp up”; sub “Apply every other day for 1–2 weeks before moving to twice daily”) is drawn from the ER “Risk Mitigation Strategies” section (lines 230–232), not the
Protocolsection as 10.2 requires; the Protocol section offers other actionable aspects (e.g., morning application paired with sunscreen, ER line 249). - 11.1 — Tolerability check is not time-to-effect: time_3 (“First tolerability check — 4 weeks”) is a monitoring/tolerability milestone (ER Monitoring, line 318), not a time-to-effect aspect; the ER documents only firmness and wrinkle outcomes (both ~8–12 weeks) as genuine time-to-effect data.
Fixes 26/06/2026 12:30
- 10.2 — Action sourced from Protocol section: Replaced action_3 “Onboarding / Patch test, then ramp up” (sourced from Risk Mitigation) with “Best time of day / Morning + evening” and sub “Morning application pairs naturally with sunscreen; no specific circadian timing required”, drawn from the ER
Protocolsection (line 249). - 11.1 — Removed non-time-to-effect set: Removed time_3 “First tolerability check / 4 weeks” (a monitoring milestone, not time-to-effect) and set its pcell to display:none with placeholders restored, since the ER provides only two genuine time-to-effect aspects (firmness and fine lines, both ~8–12 weeks).
Issues 26/06/2026 12:23
- 3.1 — Misspelled Benefits comment marker: The HTML section comment for the Benefits card reads “BENEFTIS” (line 517) instead of “BENEFITS”; while it is a non-rendering comment and does not alter any visible fixed heading, it is an integrity defect in the template structure.
Fixes 26/06/2026 12:23
- 3.1 — Misspelled Benefits comment marker: Corrected the Benefits card section comment from “BENEFTIS” to “BENEFITS” (line 517).